These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1108 related items for PubMed ID: 19300099

  • 1. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
    Fries P, Runge VM, Bücker A, Schürholz H, Reith W, Robert P, Jackson C, Lanz T, Schneider G.
    Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
    [Abstract] [Full Text] [Related]

  • 2. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model.
    Runge VM, Biswas J, Wintersperger BJ, Baumann SS, Jackson CB, Herborn CU, Patel T.
    Invest Radiol; 2006 Mar; 41(3):244-8. PubMed ID: 16481906
    [Abstract] [Full Text] [Related]

  • 3. Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents.
    Wintersperger BJ, Runge VM, Tweedle MF, Jackson CB, Reiser MF.
    Invest Radiol; 2009 Feb; 44(2):89-94. PubMed ID: 19077910
    [Abstract] [Full Text] [Related]

  • 4. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators.
    Essig M, Tartaro A, Tartaglione T, Pirovano G, Kirchin MA, Spinazzi A.
    Acad Radiol; 2006 Jun; 13(6):744-51. PubMed ID: 16679277
    [Abstract] [Full Text] [Related]

  • 5. Brain tumor enhancement in MR imaging at 3 Tesla: comparison of SNR and CNR gain using TSE and GRE techniques.
    Wintersperger BJ, Runge VM, Biswas J, Reiser MF, Schoenberg SO.
    Invest Radiol; 2007 Aug; 42(8):558-63. PubMed ID: 17620938
    [Abstract] [Full Text] [Related]

  • 6. Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0 T using high-relaxivity contrast agents.
    Huang B, Liang CH, Liu HJ, Wang GY, Zhang SX.
    Acta Radiol; 2010 Feb; 51(1):78-84. PubMed ID: 19912078
    [Abstract] [Full Text] [Related]

  • 7. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
    Liang J, Sammet S, Yang X, Jia G, Takayama Y, Knopp MV.
    Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
    [Abstract] [Full Text] [Related]

  • 8. Assessment of myocardial viability using delayed enhancement magnetic resonance imaging at 3.0 Tesla.
    Klumpp B, Fenchel M, Hoevelborn T, Helber U, Scheule A, Claussen C, Miller S.
    Invest Radiol; 2006 Sep; 41(9):661-7. PubMed ID: 16896300
    [Abstract] [Full Text] [Related]

  • 9. Cerebral blood volume quantification in a C6 tumor model using gadolinium per (3,6-anhydro) alpha-cyclodextrin as a new magnetic resonance imaging preclinical contrast agent.
    Lahrech H, Perles-Barbacaru AT, Aous S, Le Bas JF, Debouzy JC, Gadelle A, Fries PH.
    J Cereb Blood Flow Metab; 2008 May; 28(5):1017-29. PubMed ID: 18183033
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
    Hsu JS, Jaw TS, Liu GC, Wang YM, Chen SH, Kuo YT, Jao JC, Li CW, Tsai KB.
    J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength.
    Fries P, Massmann A, Robert P, Corot C, Laschke MW, Schneider G, Buecker A, Müller A.
    Invest Radiol; 2019 Sep; 54(9):549-558. PubMed ID: 31033675
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI.
    Hirschberg H, Wu GN, Madsen SJ.
    Minim Invasive Neurosurg; 2007 Dec; 50(6):318-23. PubMed ID: 18210352
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T.
    Morelli JN, Runge VM, Vu L, Loynachan AT, Attenberger UI.
    Invest Radiol; 2010 Dec; 45(12):810-8. PubMed ID: 20856127
    [Abstract] [Full Text] [Related]

  • 14. Comparison of Gd-DTPA-induced signal enhancements in rat brain C6 glioma among different pulse sequences in 3-Tesla magnetic resonance imaging.
    Sato H, Enmi J, Teramoto N, Hayashi T, Yamamoto A, Tsuji T, Naito H, Iida H.
    Acta Radiol; 2008 Mar; 49(2):172-9. PubMed ID: 18300142
    [Abstract] [Full Text] [Related]

  • 15. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.
    Attenberger UI, Runge VM, Jackson CB, Baumann S, Birkemeier K, Michaely HJ, Schoenberg SO, Reiser MF, Wintersperger BJ.
    Invest Radiol; 2009 May; 44(5):251-6. PubMed ID: 19550376
    [Abstract] [Full Text] [Related]

  • 16. Contrast-enhanced magnetic resonance angiography: evaluation of the high relaxivity low diffusible gadolinium-based contrast agent P846 in comparison with gadoterate meglumine in rabbits at 1.5 Tesla and 3.0 Tesla.
    Peldschus K, Hamdorf M, Robert P, Port M, Graessner J, Adam G, Herborn CU.
    Invest Radiol; 2008 Dec; 43(12):837-42. PubMed ID: 19002055
    [Abstract] [Full Text] [Related]

  • 17. Dynamic contrast enhancement of experimental glioma an intra-individual comparative study to assess the optimal time delay.
    Engelhorn T, Schwarz MA, Eyupoglu IY, Kloska SP, Struffert T, Doerfler A.
    Acad Radiol; 2010 Feb; 17(2):188-93. PubMed ID: 19910218
    [Abstract] [Full Text] [Related]

  • 18. P03277-A New Approach to Achieve High-Contrast Enhancement: Initial Results of an Experimental Extracellular Gadolinium-Based Magnetic Resonance Contrast Agent.
    Fries P, Müller A, Seidel R, Robert P, Denda G, Menger MD, Schneider G, Buecker A.
    Invest Radiol; 2015 Dec; 50(12):835-42. PubMed ID: 26186281
    [Abstract] [Full Text] [Related]

  • 19. 3.0 Tesla high spatial resolution contrast-enhanced magnetic resonance angiography (CE-MRA) of the pulmonary circulation: initial experience with a 32-channel phased array coil using a high relaxivity contrast agent.
    Nael K, Fenchel M, Krishnam M, Finn JP, Laub G, Ruehm SG.
    Invest Radiol; 2007 Jun; 42(6):392-8. PubMed ID: 17507810
    [Abstract] [Full Text] [Related]

  • 20. Magnetic resonance coronary angiography: comparison between a Gd-BOPTA- and a Gd-DTPA-enhanced spoiled gradient-echo sequence and a non-contrast-enhanced steady-state free-precession sequence.
    Nassenstein K, Breuckmann F, Hunold P, Barkhausen J, Schlosser T.
    Acta Radiol; 2009 May; 50(4):406-11. PubMed ID: 19308763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.